{"id":1469,"date":"2018-10-12T13:43:05","date_gmt":"2018-10-12T13:43:05","guid":{"rendered":"https:\/\/touchrespiratory.com\/media_gallery\/mark-l-metersky-chest-2018-empiric-antibiotic-therapy-challenges-and-recommendations\/"},"modified":"2019-03-15T16:13:27","modified_gmt":"2019-03-15T16:13:27","slug":"mark-l-metersky-chest-2018-empiric-antibiotic-therapy-challenges-and-recommendations","status":"publish","type":"media_gallery","link":"https:\/\/touchrespiratory.com\/respiratory-infections\/conference-hub\/mark-l-metersky-chest-2018-empiric-antibiotic-therapy-challenges-and-recommendations\/","title":{"rendered":"Mark L Metersky, CHEST 2018 \u2013 Empiric antibiotic therapy: challenges and recommendations"},"content":{"rendered":"<p><b>Mark L Metersky<\/b> (University of Connecticut School of Medicine, Farmington, CT, US) discusses current recommendations and guidelines with respect to the use of empiric antibiotic therapy in patients with ventilator-associated pneumonia.<\/p>\n<p><b>Questions<\/b><\/p>\n<p>1. What are the major challenges of empiric antibiotic therapy in patients with ventilator-associated pneumonia? (0:10)<br \/>\n2. How are patients defined in terms of risk when selecting antibiotic treatment? (1:49)<br \/>\n3. What are the recommendations of the latest guidelines in the treatment of patients with risk factors for multidrug resistance and high mortality risk? (2:59)<br \/>\n4. What is the current recommended antibiotic treatment duration for high- and low-risk patients? (3:25)<br \/>\n5. What are the limitations of the current guidelines? (6:03)<\/p>\n<p>Speaker disclosure: Mark L Metersky has nothing to disclose in relation to this video interview.<\/p>\n<p><b>Filmed at the CHEST Annual Meeting, San Antonio, TX, US, October 2018.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mark L Metersky (University of Connecticut School of Medicine, Farmington, CT, US) discusses current recommendations and guidelines with respect to the use of empiric antibiotic therapy in patients with ventilator-associated pneumonia. Questions 1. What are the major challenges of empiric antibiotic therapy in patients with ventilator-associated pneumonia? (0:10) 2. How are patients defined in terms [&hellip;]<\/p>\n","protected":false},"featured_media":1470,"template":"","class_list":["post-1469","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-respiratory-infections","vocabulary_1-respiratory-intensive-care","vocabulary_1-ventilation","video_categories-chest-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery\/1469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":0,"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery\/1469\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media\/1470"}],"wp:attachment":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media?parent=1469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}